Xofylin-AX Tablet is a combination medication containing Doxofylline 400 mg and Ambroxol 30 mg, indicated for the management of respiratory conditions characterized by bronchospasm and excessive mucus production. Doxofylline, a xanthine derivative, acts as a bronchodilator by inhibiting phosphodiesterase enzymes, leading to relaxation of bronchial smooth muscles and improved airflow in obstructive airway diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Ambroxol serves as a mucolytic agent, facilitating the breakdown and clearance of mucus by stimulating surfactant production and enhancing mucociliary transport, thereby improving expectoration and airway patency. The synergistic effect of these active ingredients provides effective relief from symptoms including breathlessness, wheezing, and productive cough. Xofylin-AX is typically administered orally, with dosage tailored according to clinical severity and patient response. It is generally well-tolerated; however, caution is advised in patients with cardiac arrhythmias, peptic ulcers, or hypersensitivity to xanthines or ambroxol. Common adverse effects may include gastrointestinal discomfort, headache, and mild nervousness. This combination therapy offers a comprehensive approach to managing obstructive airway diseases by addressing both bronchoconstriction and mucus hypersecretion, thereby enhancing respiratory function and patient quality of life.